Introduction: ECMO provides respiratory and circulatory support in critically ill patients. In our study, we report on a single center experience with ECMO and aim to identify the prognostic markers for survival to discharge from hospital. Methods: A registry was maintained on all patients who underwent ECMO implantation from September 2012 till January 2016 at a single institution. The collected data was analyzed to identify baseline characteristics, outcomes including clinical variables predictive of poor outcome. Results: A total of 29 patients underwent ECMO implantation. The average age of patients was 42 AE 18 years. 59% were males (N = 17). 19 cases had a cardiac indication for ECMO (66%) while 10 cases had a pulmonary indication (34%). On univariate analysis; presence of Multi-organ failure, SOFA score more than 18 and hemoglobin less than 10 g/dl at baseline and after ECMO removal were associated with increased 30 day mortality. Pearson correlation with 30 day mortality showed a positive correlation with MOF (+0.562, p = 0.002) and SOFA score >18 (+0.448, p = 0.015) and a negative correlation with anemia (À0.507, p = 0.005). 15 out of the total 29 patients (52%) died within 30 days of admission. Patients with MOF (log rank: 10.926, p = 0.001), SOFA score >18 (log rank: 7.758, p = 0.005) and hemoglobin <10 g/dl (log rank: 5.595, p = 0.018) had decreased survival on 30 day follow up. Conclusions: Although the use of ECMO as a last line in the treatment of critical patients refractory to conventional treatment measures constitutes an important improvement in their care; with 48% overall survival; patient selection and timing of ECMO initiation remains challenging. Patients who already had signs of MOF and a high SOFA score portended a poor response. Similarly for anemic patients. Hence the importance of consideration for ECMO use earlier in course of illness rather than later. Screening and aggressive treatment of anemia in those patients may help improve the outcomes.
Introduction
Extracorporeal membrane oxygenation (ECMO) uses a modified cardiopulmonary circuit to provide respiratory and circulatory support in critically ill patients. Recent advances in circuitry has improved its safety profile, made it easier to use in terms of implementation and decreased the number of staff needed to manage the device. Increasing evidence and experience with ECMO resulted in a steady incline in its popularity for the management of cardiopulmonary diseases1,2. ECMO is being utilized as the supportive treatment of choice for conditions with high morbidity and mortality, yet they are potentially reversible. This encompasses both cardiac and respiratory conditions such as ARDS, cardiogenic shock due it ischemia or otherwise. The 2012 the extracorporeal life support organization (ELSO) registry reported a Indian Heart Journal 69 (2017) [762] [763] [764] [765] [766] Contents lists available at ScienceDirect
Indian Heart Journal j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / i h j survival to discharge rate of 55% and 39% among adults treated with ECMO for respiratory and cardiac causes, respectively2. The CESAR trial demonstrated a significant reduction in mortality among patients with ARDS treated with ECMO compared to conventional treatment (37% versus 53%).3 ECMO use in refractory cardiogenic shock reported an overall survival of 49% 4. In cardiac arrest, patients demonstrated a survival to discharge rate of 27%2. Our group has reported earlier on use of ECMO among patients with severe cardiotoxicity due to Aluminum Phosphide intoxication8. In another series among 45 patients with Aluminum Phosphide induced cardiac intoxication and shock; those treated with ECMO had an improved survival of 33% vs. 14% among patients treated conventionally9. Albeit this there are no large randomized controlled trials demonstrating the benefit of ECMO for cardiac causes.
Furthermore there is a paucity of data guiding the selection of patients who can benefit the most from ECMO support. In our study, we report a single center experience with ECMO in patients for both cardiac and pulmonary indications and aim to identify the prognostic markers for 30 day survival.
Method

Study design
A prospectively maintained registry for all patients implanted with ECMO at Al Qassimi Hospital, Sharjah; since December 2012, till January 2016. We collected all baseline and outcome data on enrolled patients who underwent ECMO implantation with Cardiohelp system (Maquet Cardiovascular). Patients had either a cardiac or a respiratory indication for ECMO use. Respiratory indication included refractory respiratory failure of any cause and immediate respiratory collapse with or without cardiovascular instability. Cardiac indication included cardiogenic shock despite adequate other treatment measures such as volume resuscitation, inotropic and vasopressor support, and intra-aortic balloon counter-pulsation. Standard protocols during ECMO implantation and weaning were followed.
Predictor variables
Patient demographics and clinical characteristics such as hypertension, diabetes, ischemic heart disease, chronic kidney disease and sepsis were recorded. During the hospital course, the onsets of the following were documented; acute kidney injury was diagnosed if dialysis became required or serum creatinine rose above 3.0 mg/dl with urine output of less or equal to 400 ml per day. Sepsis was labeled if diagnosed by the treating physician and was proven by culture from a body site. Major bleeding was labeled upon requirement of transfusion of at least one unit of packed red blood cell. Minor bleeding was recognized if it culminated in a new onset hematoma, hematuria; but did not require blood transfusion. Heparin induced thrombocytopenia (HIT) was documented if platelet levels dropped after the start of intravenous heparin or low molecular weight enoxaparin and improved after discontinuation. Stroke was labeled if diagnosed by a neurologist with radiological evidence. Cardiac function was examined using conventional 2 D echocardiogram. Multi-organ failure (MOF) was defined as altered function involving two or more organs. In addition, Sequential Organ Failure Assessment (SOFA)5 was calculated for each patient.
Outcome variables
Patients were followed over the course of their hospital stay up to their discharge. If not discharged then survival at 30 days was recorded. During their period of ECMO use all complications the ensued were recorded.
Statistical analysis
Continuous variables were reported as mean AE standard deviation while categorical variables were reported as count (percent). Two sided t-test was used to assess differences between continuous variables, while discrete variables were assessed with Fisher's Exact test or chi square test as deemed appropriate. Simple correlations between predictor variables with outcomes were conducted. Correlations were expressed with r+ correlation coefficient and p values were placed. P value of <0.05 (two sided) was considered statistically significant. After adjusting for clinical variables, binary logistic regression analysis and forward selection models were used to assess the value of each independent variable to predict 30 day mortality. A Kaplan-Meier method was performed to estimate the cumulative survival at 30 days. A comparative log-rank test was used to compare the survival rates between different subgroups and a stepwise multivariable Cox proportional hazards model was used to identify clinical variables that can predict 30 day mortality. The hazard ratio was estimated within its 95% confidence limit and supported by the significance level. IBM SPSS Statistics for Windows (Version 22.0). Armonk, NY: IBM Corp was used to conduct the statistical analysis.
Results
Patient clinical characteristics
A total of 29 patients underwent ECMO implementation from September 2012 to January 2016 ( Table 1 ). The average age of patients was 42 AE 18years with majority being males (59%, N = 17). 19 cases (66%) had a cardiac indication for ECMO while 10 cases (34%) had a pulmonary indication. 34.5% (N = 10) of patients had ischemic heart disease, 24.1% of patients were hypertensive (N = 7) diabetic (N = 7) and septic before implantation (N = 7); while 6.9% (N = 2) had chronic kidney disease. 37.9% of patients (N = 11) developed MOF with an average SOFA score of 17.1 AE 3.8. (Table 2) During the course of the inpatient stay 55.2% (N = 16) of patients developed acute kidney injury, 44% (N = 13) developed minor bleed, 38% (N = 11) developed heparin induced thrombocytopenia (HIT), 17.2% (N = 5) developed cerebrovascular accident, and 13.8% (N = 4) developed infection at insertion site. (Table 2) On univariate analysis, MOF, SOFA score more than 18 and hemoglobin less than 10 g/dl at baseline and after ECMO removal were associated with increased 30 day mortality. Pearson correlation showed a positive correlation between MOF and 30 day mortality (+0.562, p = 0.002) and between SOFA score > 18 and 30 day mortality (+0.448, p = 0.015) and a negative correlation with anemia (-0.507, p = 0.005).
Overall survival
At 30 days, 14 out of the total 29 patients (48%) survived to discharge from hospital. Looking at the 15 patients who where deceased (52%); factors associated with decreased survival where presence of MOF (log rank:10.926, p = 0.001), a SOFA score > 18 (log rank:7.758, p = 0.005) and hemoglobin < 10 g/dl (log rank:5.595, p = 0.018) (Fig. 1 ).
Discussion
ECMO is a powerful treatment option for critically ill patients. While in many centers in the first world it can be used as a bridge for left ventricular assist device or for heart and lung transplantation, in our center, among other centers around the world, its use is limited due to limited availability of ECMO resources and decreased availability of these transplant options. Two patients fitted with ECMO became crucially dependant on it for survival and finally died due to lack of readily available transplant options. The first patient was a case of severe postpartum dilated cardiomyopathy, who could not be transferred for subsequent heart transplant and died after 3 weeks due to peripheral complications. An ECMO placed in VA configuration intakes blood from a large vein such as Inferior vena cava and pumps it continuously into a large peripheral artery such as common iliac. In doing so it tends to pump against the flow of blood from the left ventricle, which would then be preferentially diverted to the head and upper extremities while the abdomen and lower extremities become preferentially perfused by flow from ECMO. In some cases the acute increase in afterload would be large as to cause an extra burden on an already weakened Left ventricle and cause further deterioration of its systolic function. In our specific patient her aortic valve had ceased to open and she eventually developed a thrombus in her left ventricle.
In similar cases, when VA ECMO is used, LV systolic function needs careful monitoring and follow up with serial echocardiograms and consideration for use of inotropes to aid the left ventricle and if possible quick weaning of ECMO as tolerated.
The other patient had developed end stage lung disease following a prolonged course of ventilation due to H1N1 pneumonia and ARDS and could not be transferred for lung transplant and died after 2 weeks due to sepsis Hence most of our emphasis lies upon its use as a bridge for recovery and the ability to foresee who would be a potential candidate in order to achieve a favorable final outcome. To our knowledge this is the first report from our region in the Middle East that details the indication for ECMO use, baseline patient characteristics, and short term outcomes for patients treated by it.
In our series, we present 29 patients who required ECMO for both pulmonary and cardiac indications. The mean age of the study population was comparatively younger than reported elsewhere in literature. 31% of our patients (N = 9) had ongoing CPR while ECMO was being implanted out of which 34% (N = 3) survived to hospital discharge which is similar to the rate reported in literature6. However, this came at the expense of potential complications such as access site infection, HIT, bleeding. In univariate analysis we found that a hemoglobin level less than 10 g/dl on admission and after ECMO removal is associated with increased 30 day mortality. ECMO circuits require the introduction of large bore catheters into venous and arterial peripheral circulation and this can invariably invite complications such as bleeding from multiple initial puncture attempts or due to patients being on heparin intravenously with high Activated clotting times. ECMO may also induce hemolysis by a number of mechanisms the most common ones being due to generation of negative pressure by the pump in hypovolemic patients, the development of clot within the circuit or near the cannula orifices or excessive centrifugal pump speed >3000 revolutions per minute (RPM)7. Therefore, ECMO can exacerbate pre-existing anemia and patients undergoing ECMO implantation should be aggressively screened for anemia and transfused to improve outcomes. It is also conceivable that anemia is a marker for sicker patients who would faire worst. The link between mortality and anemia among patients requiring ECMO needs further validation, and if so postulation of treatment goals. The other factors associated with poor 30 day survival were presence of MOF at implantation time, and a SOFA score more than18. SOFA score is a quantitative measurement of degree of MOF and describes the spectrum of the same pathologic process. Persistent organ failure is a common pattern seen before death7 and a marker for poor prognosis. SOFA score is a scoring system which describes the status of patients organ function and higher scores are predictive of mortality5. What we can infer from our finding is that ECMO does not offer any mortality benefit in patients with high SOFA score or MOF. This highlights the question of timing of implantation; are we actually doing any good to patients when we implant ECMO in patients when their illness becomes resistant to all other treatment options and they are already in refractory MOF. This is especially relevant in developing countries where there are no options for organ transplantation and emphasis is on "bridge to recovery" pathway. Earlier implantation of ECMO may help improve patient outcomes. Furthermore the use SOFA score when screening patients for ECMO implantation can help quantify when is timing appropriate before it becomes too late. To our knowledge this is the first report that highlight the use of SOFA score for this indication.
Limitation
The most important limitation of this registry is the sample size. When analyzed with logistic regression and Cox regression; there is a statistically significant odds ratio and hazard ratio for MOF, SOFA score and anemia. However, due to the small sample size the confidence intervals are very wide and hence the results are not included in the final report. Moreover, our population varied in terms of age and ECMO indication as a result of which our distribution might have been skewed. Nonetheless, we shed light on use of ECMO from our region and obstacles to which we are exposed and the outcomes that are attainable. This registry is continuous and as the patient number grows any significant associations can be reaffirmed and reported.
Conclusion
ECMO is a supportive option for patients with refractory cardiogenic shock and respiratory failure. The patients who will benefit the most are still not defined in the literature. From our report, we infer that patients who develop advanced multi organ dysfunction and have a SOFA score more than 18 are poor candidates to benefit from ECMO as a bridge to recovery. Moreover, we also show the importance of screening and treating anemia in patients who will undergo ECMO implantation.
